<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490019</url>
  </required_header>
  <id_info>
    <org_study_id>BBS V1.0</org_study_id>
    <nct_id>NCT03490019</nct_id>
  </id_info>
  <brief_title>Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement</brief_title>
  <acronym>BBS</acronym>
  <official_title>Treatment of Infantile and Juvenile Patients With Bardet-Biedl-Syndrome With Metformin. Evaluation of a Visual Improvement as a Side Effect of the Pediatric Treatment of Adipositas - a Prospective Pilot Study Without Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective pilot study without control group children and young adults (10-25 years
      old) diagnosed with Bardet-Biedl syndrome and treated with Metformin for their adipositas
      will be evaluated for a possible additional effect of Metformin on visual acuity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within experiments with animals a positive effect of Metformin concerning the photo receptors
      was shown. Several patients of the university hospital T체bingen with Bardet-Biedl-Syndrome
      and Metformin therapy due to their adipositas reported a subjective improvement of the visual
      acuity which was confirmed by opthalmologic tests.

      This will be checked in a prospective pilot study without control group including children
      and young adults (10-25 years old) diagnosed with Bardet-Biedl syndrome and treated with
      Metformin for their adipositas. Therefore a possible additional effect of Metformin on visual
      acuity will be evaluated under controlled conditions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective pilot study without control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of visual acuity according to appropriate table</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of letters read</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course visual acuity defined as number of letters read</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Static perimetry</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of results of static perimetry given by measurement of light contrast sensitivity within at least 5 central points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Kinetic perimetry</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of results of kinetic perimetry given by mapping the visual field sensitivity boundaries using Goldmann perimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinogram (ERG) dim-flash</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of values of ERG dim-flash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinogram (ERG) standard flash</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of values of ERG standard flash at 3 ods/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinogram (ERG) cone-single-flash</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of values of ERG cone-single-flash at 30cd/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinogram (ERG) 30-Hz-Flicker</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of values of ERG measured by 30-Hz-Flicker in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual evoked potential (VEP) - amplitude</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of results of measurement of VEP amplitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual evoked potential (VEP) - latency time</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of results of measurement of VEP latency time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FST</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Full-Field-Stimulus Threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optical coherence tomography (OCT)</measure>
    <time_frame>Baseline to day 210</time_frame>
    <description>Course of central thickness of retina measured by OCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Bardet-Biedl Syndrome</condition>
  <condition>Visual Impairment</condition>
  <arm_group>
    <arm_group_label>Metformin Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500, 850 or 1000 mg depending on body weight once daily for 24 weeks</description>
    <arm_group_label>Metformin Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically confirmed Bardet-Biedl-syndrome

          -  Visual acuity between 0.05 and 0.8

          -  Age &gt;=10 year to &lt;25 years

          -  Visual field III4e or V4e with diameter &gt;=5째, if II4e not seen

          -  informed consent of patient and/or legal representative

        Exclusion Criteria:

          -  Hypoglycaemia (&lt;50mg/dl)

          -  Therapy with Metformin within the last three months

          -  Participation in another clinical trial

          -  pregnancy, lactation

          -  any contra indication concerning Metformin therapy

          -  Renal failure (creatinine clearance &lt; 60ml/min)

          -  any acute disorder accompanied by clouding of consciousness

          -  acute or chronic disorders possible accompanied by tissue hypoxia

          -  Liver insufficiency, alcohol abuse

          -  not fluent in German language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heiko Billing, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtit채tsklinikum T체bingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heiko Billing, PD Dr. med.</last_name>
    <phone>07071-2985480</phone>
    <email>heiko.billing@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eberhart Zrenner, Prof.</last_name>
    <phone>07071-2984786</phone>
    <email>ez@uni-tuebingen.de</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
    <mesh_term>Bardet-Biedl Syndrome</mesh_term>
    <mesh_term>Laurence-Moon Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

